number ahead estim new domest
intern opportun increas confid
tabula rasa report number exceed consensu expect
vs consensu pace continu steadi
growth servic segment outperform organ sinfoniarx
segment grew strongli recent updat focu
opioid crisi addit mtm cost medic cost
calcul increas import awar mtm servic like
draw attent trhc solut uniqu product offer
expect benefit significantli tailwind interest intern
opportun management note call increas awar mtm increas
confid stori reiter outperform rate
adj ep adj ebitda line report revenue
vs estim consensu adj ebitda vs
estim consensu adj ep vs estim
consensu estim revenue guid rais ebitda re-affirmed
believ opioid could opportun second
ad mtm start part senior part
serv via sinfonarx
manag solut overlap pace organ
substanti cross-sel possibl paid cash earnout
max thrc see accret top bottom line rev
current annual ebitda margin
intern opportun look promis management discuss interest
opportun europ provid technolog solut address rx relat
advers event look promis could largest softwar client upon
complet due expedit natur discuss believ deal
could materi toward end year could step stone
intern opportun
chang estim increas estim
strength servic revenu includ sinfoniarx
continu lift revenu number ad intang amort
lift adjust earn expect gm come
due sinfoniarx season also increas estim
proprietari
reduc
technolog servic
medic safeti patient outcom
lower healthcar cost client
analyst certif import disclosur see disclosur
tabula rasa proprietari medic risk therapi solut
enabl signific shift care elderli
pace focus elimin advers drug event
deal complex multiple-med regimen home
demograph tailwind increas use multipl medic
cost focu drive penetr non-
profit for-profit pace program trhc solut
mtm mrm solut signific relev
commerci health plan expect see wave
adopt commerci plan sinfoniarx acquisit add new
solut acceler growth
continu growth sustain oper margin improv
contract new pace organ
new commerci contract emtm medwis solut
sinfoniarx earnout pipelin convert contract
sinfoniarx earnout lift growth significantli
mix new live tilt commerci live penetr
sinfoniarx earnout convert impact expect
new market entrant pose headlin risk potenti take
regulatori chang disrupt pace adopt
target base believ increas focu medic therapi manag opioid crisi
uniqu solut set set apart like drive multipl higher
near term integr sinfoniarx acquisit convert earnout pipelin pose biggest risk stori regulatori
turmoil disrupt pace could impact growth increas attent mtm could attract competit
revenu adj ep adj ebitda in-line report revenu vs
estim consensu adj ebitda vs estim consensu
adj ep vs estim consensu estim
gm adj ebitda miss gross margin came vs estim last year
sinfonarx season member notif adj ebitda margin vs
estim last year estim
guid introduc see revenu bracket estim
consensu adj ebitda seen vs estim consensu net
incom expect vs estim consensu compani expect
signific step-up sinfona gm post member qualif season
guid adjust rais revenu guid vs
estim consensu estim adj ebitda guid re-affirmed vs
estim consensu net incom guid revis loss
fair valu adjust sinfonarx acquisit centerlight includ guid
overlap pace organ substanti cross-sel possibl paid
cash earnout max thrc see accret top bottom line rev
current annual ebitda margin
favor regulatori chang first sponsor must use real-tim opioid overdos
alert dispens pharmacist duplicate-therapi alert per letter propos due
see pmpm less emtm target program believ opioid
could opportun second ad mtm start part
senior part serv via sinfonarx
sinfonarx strong sinfonarx strongest ever medic review complet
sinfona also open fifth call center austin expand bcb
contract saa work start
pace deal centerlight challeng contract new ar pace start
three ar also sign new nc organ start summer centerlight saw ceo
chang multipl audit preclud client focus trhc result
reduc hospit meet schedul
at-risk provid group traction sign deal concierg medicin provid mdvip
mrm medic risk manag phase avail select group doc
expect grow time
intern collabor continu pursu integr recent
approach intern player one case integr eu pharmaci
research develop
sale market
gener administr
depreci amort
total expens
incom tax
dilut prefer stock warrant
compani report oppenheim estim
